Vertex Pharma (VRTX) Misses Q1 EPS by 20c; raises guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $525.73 --0%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $4.06, $0.20 worse than the analyst estimate of $4.26. Revenue for the quarter came in at $2.77 billion versus the consensus estimate of $2.86 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.85-12 billion, versus the consensus of $11.982 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Arcos Dorados (ARCO) Tops Q2 EPS by 7c
- Telesat Corporation (TSAT) Misses Q2 EPS by 1006c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
